Moderna, Inc. $MRNA Stake Cut by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 76.1% during the third quarter, HoldingsChannel reports. The firm owned 173,334 shares of the company’s stock after selling 551,496 shares during the period. Letko Brosseau & Associates Inc.’s holdings in Moderna were worth $33,379,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in MRNA. BlackRock Inc. bought a new stake in shares of Moderna in the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna during the second quarter valued at approximately $564,272,000. Merck & Co. Inc. bought a new position in shares of Moderna during the second quarter valued at approximately $161,642,545. Bamco Inc. NY bought a new position in shares of Moderna during the second quarter valued at approximately $139,317,000. Finally, Bank of New York Mellon Corp purchased a new position in Moderna during the second quarter valued at approximately $119,168,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, CFO Jamey Mock sold 34,836 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the completion of the sale, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 in the last 90 days. 10.80% of the stock is owned by corporate insiders.

Key Moderna News

Here’s some of the latest news about MRNA:

• Positive Sentiment: Moderna raised its 2026 revenue-growth outlook to 15%–25%, up from its prior forecast of growth of up to 10%. Stronger overseas COVID-19 sales and the improved outlook provide near-term support. Article: Moderna Raises 2026 Revenue Growth Forecast
• Neutral Sentiment: Moderna presented an oncology-led growth strategy, including work on its personalized cancer vaccine. That pipeline could become a meaningful source of future growth, but its commercial potential remains uncertain and will take time to establish. Article: Moderna’s Oncology Growth Plan
• Negative Sentiment: Investors focused on the cost of that strategy: Moderna expects about $4 billion in cash costs in 2027. The planned investment raises the stakes for its cancer programs and could prolong the path to profitability. Article: Moderna Analyst Day Spending

Moderna Stock Performance

MRNA stock opened at $231.35 on Friday. The firm has a market cap of $93.61 billion, a price-to-earnings ratio of -32.58 and a beta of 1.16. The firm has a 50-day simple moving average of $200.18 and a two-hundred day simple moving average of $95.52. Moderna, Inc. has a one year low of $22.28 and a one year high of $280.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $890.25 million. During the same period last year, the business earned ($0.51) EPS. The company’s revenue was up 29.2% compared to the same quarter last year. On average, equities analysts forecast that Moderna, Inc. will post -5.34 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on MRNA shares. Royal Bank Of Canada reissued a “sector perform” rating and issued a $130.00 price objective on shares of Moderna in a research note on Wednesday, August 19th. Citigroup restated a “sell” rating on shares of Moderna in a report on Friday, October 23rd. Morgan Stanley increased their target price on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 7th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Finally, UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna currently has an average rating of “Hold” and an average price target of $113.75.

Moderna Profile

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.